Biomarkers for immunotherapy: where are we?
The future is in the hands of tools built on combinations of biomarkers as no single biomarker is likely to reflect the complexity of the tumour microenvironment or account for tumour evolution
The future is in the hands of tools built on combinations of biomarkers as no single biomarker is likely to reflect the complexity of the tumour microenvironment or account for tumour evolution
Tislelizumab in combination with gemcitabine and cisplatin prolonged PFS compared with chemotherapy alone in the RATIONALE 309 study
Early clinical findings with the anti-claudin-6 CAR-T-cell product BNT211, with or without amplifying vaccine, in patients with refractory solid tumours are promising but more data are required
A study associates reductions in ctDNA with major pathologic response following neoadjuvant atezolizumab in resectable stage IB–IIIB NSCLC, but clinical application is still some way off
Sub-group analyses of CheckMate 227 part 1 provide reassurance but no definite guidance regarding standard treatment for different patient sub-groups
Results from an exploratory analysis of the IMpower010 trial confirm that there is a correlation between tumour-cell PD-L1 expression and disease-free survival
The complexity of identifying and clinically validating immunotherapy biomarkers can be addressed by broadening tumour sampling and expanding the characterisation methodologies used
Data suggest that assessing the quality as well as the quantity of tumour mutations may enhance prediction of outcomes in patients treated with immune checkpoint inhibitors
From cell-based therapies to soluble T-cell engagers and T-cell co-stimulation, early findings show novel promising strategies, although more data are needed
In-depth understanding of immunological cellular mechanisms provides the basis to explore new ways to modulate the immune system for more effective treatment of cancer
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.